Histamine and its receptors

被引:397
作者
Parsons, ME
Ganellin, CR
机构
[1] Univ Hertfordshire, Dept Life Sci, Hatfield AL10 9AB, Herts, England
[2] UCL, Christopher Ingold Labs, Dept Chem, London WC1H 0AJ, England
关键词
antihistamines; H(2)-receptor antagonists; H(3)-receptor antagonists; H(4) receptors constitutive activity; gastric acid secretion; allergy; mepyramine; burimamide; cimetidine; thioperamide; JNJ; 7777120;
D O I
10.1038/sj.bjp.0706440
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This article reviews the development of our knowledge of the actions of histamine which have taken place during the course of the 20th century. Histamine has been shown to have a key physiological role in the control of gastric acid secretion and a pathophysiological role in a range of allergic disorders. The synthesis of, and pharmacological studies on, selective agonists and antagonists has established the existence of four types of histamine receptor and histamine receptor antagonists have found very important therapeutic applications. Thus, in the 1940s, H(1)-receptor antagonists ('the antihistamines') yielded and still provide valuable treatment for allergic conditions such as hay fever and rhinitis. In the late 1970s and 1980s, H(2)-receptor antagonists (in the discovery of which the two authors were personally involved) revolutionised the treatment of peptic ulcer and other gastric acid-related diseases. The H(3)-receptor antagonists, although available since 1987, have been slower to find a therapeutic role. However, the discovery of nonimidazole derivatives such as brain-penetrating H(3) antagonists has provided drugs that are in early-phase clinical trials, possibly for application in obesity, and a variety of central nervous system disorders, such as memory, learning deficits and epilepsy. Finally, the most recently (1999) discovered H(4) receptor promises the potential to provide drugs acting on the immunological system with possible applications in asthma and inflammation.
引用
收藏
页码:S127 / S135
页数:9
相关论文
共 28 条
[11]  
Brimblecombe RW, 1975, BRIT J PHARMACOL, V53, P435
[12]  
Cooper DG, 1990, COMPREHENSIVE MED CH, V3, P323
[13]   Medicinal chemistry and biological properties of non-imidazole histamine H3 antagonists [J].
Cowart, M ;
Altenbach, R ;
Black, L ;
Faghih, R ;
Zhao, C ;
Hancock, AA .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2004, 4 (09) :979-992
[14]  
Dale HH, 1919, J PHYSIOL-LONDON, V52, P355
[15]  
Ganellin CR, 1998, ARCH PHARM, V331, P395, DOI 10.1002/(SICI)1521-4184(199812)331:12<395::AID-ARDP395>3.0.CO
[16]  
2-7
[17]  
Hill SJ, 1997, PHARMACOL REV, V49, P253
[18]  
Lewis T, 1924, HEART-J STUD CIRC, V11, P209
[19]   Distinct pharmacology of rat and human histamine H3 receptors:: role of two amino acids in the third transmembrane domain [J].
Ligneau, X ;
Morisset, S ;
Tardivel-Lacombe, J ;
Gbahou, F ;
Ganellin, CR ;
Stark, H ;
Schunack, W ;
Schwartz, JC ;
Arrang, JM .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 131 (07) :1247-1250
[20]   Cloning and functional expression of the human histamine H3 receptor [J].
Lovenberg, TW ;
Roland, BL ;
Wilson, SJ ;
Jiang, XX ;
Pyati, J ;
Huvar, A ;
Jackson, MR ;
Erlander, MG .
MOLECULAR PHARMACOLOGY, 1999, 55 (06) :1101-1107